CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
Etigilimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04761198
NCT04761198Phase 2Completed
CompareCT.gov

A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)

Mereo BioPharma·interventional·Posted Feb 18, 2021·Updated Mar 17, 2025

In Brief

A Phase 2 clinical trial evaluating Etigilimab and Nivolumab for Solid Tumor, Adult and 2 related conditions. Completed, enrolled 76 participants across 16 sites in 2 countries.

Detailed Summary

This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
CountriesUnited Kingdom, United States
CollaboratorsICON Clinical Research

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 18, 2021
Enrollment StartMar 23, 2021
Primary CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.4 years ago

Interventions

Etigilimabdrug

IV infusion of IV etigilimab every 2 weeks

Nivolumabdrug

IV infusion of nivolumab every 2 weeks